15.53
-0.27 (-1.71%)
| Penutupan Terdahulu | 15.80 |
| Jumlah Dagangan | 1,083,259 |
| Harga / Pendapatan (P/E Ke hadapan) | 24.69 |
| Harga / Jualan (P/S) | 2.98 |
| Harga / Buku (P/B) | 2.39 |
| Julat 52 Minggu | |
| Hasil Dividen (DY TTM) | 0.30% |
| Margin Keuntungan | 11.16% |
| Margin Operasi (TTM) | 13.97% |
| EPS Cair (TTM) | 0.540 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 8.70% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 40.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 27.86% |
| Nisbah Semasa (MRQ) | 1.83 |
| Aliran Tunai Operasi (OCF TTM) | 184.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -113.47 M |
| Pulangan Atas Aset (ROA TTM) | 4.88% |
| Pulangan Atas Ekuiti (ROE TTM) | 9.14% |
Sentimen Berita
-
Broader Biologics Growth Strengthens Stevanato’s (STVN) Long-Term Outlook
10 Nov, 12:47PM
-
Stevanato Group (STVN) Could Be 42% Undervalued Following Q3 Earnings
04 Nov, 4:12AM
-
Stevanato Group SpA (STVN) (Q3 2026) Earnings Call Highlights: Revenue Climbs 8% as Non-GLP ...
03 Nov, 3:07PM
-
Stevanato Group (STVN) Faces Legal Investigation Over GLP 1 Disclosure
04 Nov, 6:15AM
-
Why Stevanato Group Bears Were Right Before The Drop
04 Nov, 4:10PM
AISkor Stockmoo
| Nilai 30% | 0.7 |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Lebih murah daripada penilaian biasanya. info | |
| Hutang rendah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info | |
| Masa 30% | -3.5 |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga turun. Kenaikan terkini melepasi rintangan belum disahkan. info | |
| Corak pembalikan menaik baru-baru ini: Engulfing menaik. info | |
| Di bawah garis aliran jangka sederhana. info | |
| Sentimen 20% | 0.1 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini bercampur atau neutral. info | |
| Wang Pintar 20% | 2.1 |
| Orang dalam membeli bersih baru-baru ini. info | |
| Institusi bersih +12.52% daripada saham dalam pemfailan 13F terkini: 67 pemegang menambah, 69 mengurang (suku berakhir 30 Sep 2026). info | |
| Keadaan pasaran dan sektor neutral. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor mengatasi prestasi pasaran. | |
| Tonggak-tonggak tidak sependapat, jadi skor dilemahkan. | |
| Tidak dikira dalam skor | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info | |
| Harga di antara sokongan dan rintangan. info | |
| Skor Akhir | -0.33 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Instruments & Supplies (US) | Bercampur | Bercampur |
| Medical Instruments & Supplies (Global) | Bercampur | Bercampur | |
| Stok | Stevanato Group S.p.A. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| STVN | - | 0.30% | - | 2.39 |
| ALC | - | 0.49% | - | 1.64 |
| RMD | - | 1.08% | - | 5.66 |
| BDX | - | 2.20% | - | 2.41 |
| WST | - | 0.37% | - | 9.67 |
| BLCO | - | - | - | 1.17 |
|
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America. |
|
| Sektor | Healthcare |
| Industri | Medical Instruments & Supplies |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 1.68% |
| % Dimiliki oleh Institusi | 112.67% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Nicholas Company, Inc. | 30 Sep 2026 | 743,799 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| MOREL DONALD E JR | 13.57 | - | 25,000 | 339,250 |
| Jumlah Keseluruhan Kuantiti Bersih | 25,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 339,250 | |||
| Purata Pembelian Keseluruhan ($) | 13.57 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MOREL DONALD E JR | Pengarah | 06 Nov 2026 | Beli (+) | 25,000 | 13.57 | 339,250 |
Institusi
Pemilikan institusi: 94.54%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 67 | 8,329,131 |
| Berkurang | 69 | 6,219,678 |
| Baharu | 28 | 5,656,951 |
| Dijual habis | 23 | 1,508,891 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Nov 2026 | Yahoo Finance |
Stevanato Group to Participate in Upcoming Investor Conferences
PIOMBINO DESE, Italy, November 16, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming… |
| 10 Nov 2026 | Yahoo Finance |
Broader Biologics Growth Strengthens Stevanato’s (STVN) Long-Term Outlook
Cooper Investors, an investment management firm, released its third-quarter 2026 investor letter for “Cooper Investors Global Equities Fund (Unhedged)”. The letter can be downloaded here. The Fund returned 0.50% net of fees in the quarter, driven by Compounding and Real Asset investments, partially… |
| 04 Nov 2026 | Yahoo Finance |
Why Stevanato Group Bears Were Right Before The Drop
Stevanato Group kept reporting healthy headlines, with Q4 and Q1 updates pointing to solid revenue growth, stronger high-value solutions and reaffirmed guidance. Holding Stevanato Group over the past year would have meant a 42.8% loss, including dividends. If you had bought in believing GLP-1… |
| 04 Nov 2026 | Yahoo Finance |
Stevanato Group (STVN) Faces Legal Investigation Over GLP 1 Disclosure
Stevanato Group (NYSE: STVN) faces a pending legal investigation into its disclosures after revising its GLP-1-related volume outlook. Law firm SueWallSt is examining whether Stevanato Group complied with U.S. securities disclosure rules following guidance on lower GLP-1 volumes. The probe focuses… |
| 04 Nov 2026 | Yahoo Finance |
Stevanato Group (STVN) Could Be 42% Undervalued Following Q3 Earnings
Stevanato Group (STVN) just posted its third quarter 2026 earnings, reporting sales of €326.1 million and net income of €41.8 million. These results give investors fresh numbers to reassess the stock. Despite the solid Q3 report and the Aptar Pharma collaboration announced in late October… |
| 04 Nov 2026 | Yahoo Finance |
Stevanato Group Q3 Earnings Call Highlights
Stevanato Group (NYSE:STVN) reported third-quarter 2026 revenue growth of 8% to €326.1 million, supported by continued expansion in its biopharmaceutical and diagnostic solutions business despite weaker demand tied to GLP-1 therapies and a decline in its engineering segment. Chairman and Chief Exec… |
| 03 Nov 2026 | Yahoo Finance |
Stevanato Group S.p.A. Q3 2026 Earnings Call Summary
Moby summary of Stevanato Group S.p.A.'s Q3 2026 earnings call… |
| 03 Nov 2026 | Yahoo Finance |
Stevanato (STVN) Q3 2026 Earnings Call Transcript
Biologics demand held firm while GLP-1 volumes shape the 2027 outlook. |
| 03 Nov 2026 | Yahoo Finance |
Stevanato Group SpA (STVN) (Q3 2026) Earnings Call Highlights: Revenue Climbs 8% as Non-GLP ...
Stevanato Group SpA (STVN) delivered solid Q3 2026 organic growth and margin expansion while flagging a temporary, single-customer GLP-1 volume decline expected to moderate 2027 growth. |
| 03 Nov 2026 | Yahoo Finance |
Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +5.88% and +3.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 03 Nov 2026 | Yahoo Finance |
Stevanato: Q3 Earnings Snapshot
PADUA, Italy (AP) — PADUA, Italy (AP) — Stevanato Group SpA (STVN) on Tuesday reported third-quarter earnings of $48.The Padua, Italy-based company said it had profit of 17 cents per share. |
| 03 Nov 2026 | Yahoo Finance |
Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
PIOMBINO DESE, Italy, November 03, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of… |
| 28 Oct 2026 | Yahoo Finance |
Stevanato Group S.p.A. (STVN) Rallies on 2Q26 Revenue Growth and EBITDA Margin Expansion
Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here. In 2026, Small Caps initially outperformed but faced challenges in the third quarter, marked by the Russell 2000 Growth Index’s -9.4% decline versus the S&P… |
| 27 Oct 2026 | Yahoo Finance |
Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection
CRYSTAL LAKE, Ill., October 27, 2026--Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection… |
| 27 Oct 2026 | Yahoo Finance |
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
PIOMBINO DESE, Italy, October 27, 2026--Stevanato Group S.p.A. (NYSE: STVN) (the "Company"), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Aptar Pharma… |
| 20 Oct 2026 | Yahoo Finance |
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
PIOMBINO DESE, Italy, October 20, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third… |
| 01 Oct 2026 | Yahoo Finance |
Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American Injectables
Ensera, a global CDMO specializing in commercialization support for injectable drug programs, has launched the Ensera Alliance Network, bringing together leading device platform and fill-finish specialists to address the complexity of commercializing drug-device combination products. |
| 01 Oct 2026 | Yahoo Finance |
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?
United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
| 18 Sep 2026 | Yahoo Finance |
electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar?
electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
| Papar semua | ||
| Hasil Dividen (DY TTM) | 0.30% |
| Purata Hasil Dividen 4T | 0.19% |
| Nisbah Pembayaran | 11.52% |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 04 Jun 2024 | 10 Apr 2024 | 15 Jul 2024 | 0.0573 Tunai |
| 07 Jun 2023 | 05 Apr 2023 | 17 Jul 2023 | 0.0577 Tunai |
| 13 Jun 2022 | 11 Apr 2022 | 13 Jul 2022 | 0.0546 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2024 | 0.057 | 1 | 0.26 |
| 2023 | 0.058 | 1 | 0.21 |
| 2022 | 0.055 | 1 | 0.30 |
Isyarat Terkini corak lilin dan silang EMA
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |